Indication: Myeloproliferative Neoplasm
A Phase 1 Open-Label Study Evaluating the Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination with Ruxolitinib in Myeloproliferative Neoplasm Subjects
Sub-indication: Hematological Malignancies
Study Type: Drug Study
Principal Investigator: Don Stevens, M.D.Norton Cancer Institute
Sponsor: Sponsor: AbbVie